FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> Wyeth | Vaccine | Prevnar-13

Wyeth's PCV vax better than current blockbuster

  • Email
  • Print
  • Comment
  • Contact Author
  • Reprint

Wyeth's investigational pneumococcal vaccine (PCV) for young children, Prevnar-13, appears to offer better protection than the current blockbuster vaccine, Prevnar. The New Jersey-based company presented data from four European studies on Monday, including a 604-infant trial conducted in Germany.

Wyeth has high hopes for Prevnar-13, which is designed to protect against six more disease-causing types of the bacteria streptococcus pneumoniae than Prevnar, including the most harmful strain, 19A. Worldwide sales of Prevnar grew by 13 percent in the third quarter and has been responsible for revenue of more than $2 billion a year to date. According to the CDC, as of 2006, Prevnar--the only PCV currently approved for young children--had reduced the incidence of invasive pneumococcal disease in children 5 and under by nearly 80 percent in the U.S. Wyeth hopes Prevnar-13 will increase the prevention rate to 92 percent.

The company, which plans to submit its application to the FDA early next year, hopes to expand sales of the vax into developing countries as well.

- check out the WSJ article for more

Related Articles: 
Wyeth - Biotech Market Share Report
Wyeth's Prevnar produces resistant strain of strep
Whistle-blowers allege problems with Wyeth's Prevnar

More stories about Wyeth   Vaccine   Prevnar-13  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.